Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System-Reference-Cited by-同舟云学术

Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System

Published:2022-10-27 Issue:11 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Dryden-Peterson Scott¹²³⁴⁵,Kim Andy¹⁶⁵,Joyce Mary-Ruth¹,Johnson Jennifer A¹⁵,Kim Arthur Y⁶⁵,Baden Lindsey R¹⁵,Woolley Ann E¹⁵

Affiliation:

1. Brigham and Women's Hospital , Boston, Massachusetts , USA

2. Dana Farber Cancer Institute , Boston, Massachusetts , USA

3. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts , USA

4. Botswana Harvard AIDS Institute , Gaborone , Botswana

5. Harvard Medical School , Boston, Massachusetts , USA

6. Massachusetts General Hospital , Boston, Massachusetts , USA

Abstract

Abstract There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).

Funder

Harvard University Center for AIDS Research

CFAR

National Institutes of Health

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac565/46650427/ofac565.pdf

Reference17 articles.

1. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants;Takashita;New Engl J Med,2022

2. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during the omicron BA.1 and BA.1.1-predominant phase;Aggarwal;Int J Infect Dis

3. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab;Food and Drug Administration

4. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19;Dougan;MedRxiv

5. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019;Ganesh;J Infect Dis,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential role of essential oils in boosting immunity and easing COVID-19 symptoms;Clinical Traditional Medicine and Pharmacology;2024-03

2. Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID‐19 infection at an ambulatory cancer center;Transplant Infectious Disease;2024-01-08

3. Interface‐Guided Computational Protein Design Reveals Bebtelovimab‐Resistance Mutations in SARS‐CoV‐2 RBD: Correlation with Global Viral Genomes and Bebtelovimab‐Escape Mutations;ChemistrySelect;2023-12-11

4. The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis;Journal of Infection;2023-07

5. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19;Annals of Internal Medicine;2023-04